Clinical Trial: CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890025) titled 'CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study' on Oct. 16.

Brief Summary: This is a Phase I/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Intervention: BIOLOGICAL: MB-CART19.1

MB-CART19.1 are autologous T cells genetically modified to express a chimeric ...